Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells $78,348.40 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) major shareholder Endurance (Cayman) Ltd Svf sold 12,844 shares of the company’s stock in a transaction dated Thursday, October 16th. The stock was sold at an average price of $6.10, for a total transaction of $78,348.40. Following the completion of the sale, the insider owned 15,340,494 shares in the company, valued at $93,577,013.40. This represents a 0.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

• On Wednesday, October 15th, Endurance (Cayman) Ltd Svf sold 16,671 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.07, for a total transaction of $101,192.97.
• On Friday, October 10th, Endurance (Cayman) Ltd Svf sold 2,300 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.08, for a total transaction of $13,984.00.
• On Thursday, October 9th, Endurance (Cayman) Ltd Svf sold 249,060 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.14, for a total transaction of $1,529,228.40.
• On Wednesday, October 8th, Endurance (Cayman) Ltd Svf sold 466,242 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.05, for a total transaction of $2,820,764.10.
• On Tuesday, October 7th, Endurance (Cayman) Ltd Svf sold 72,133 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.60, for a total transaction of $403,944.80.
• On Monday, October 6th, Endurance (Cayman) Ltd Svf sold 73,955 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.69, for a total transaction of $420,803.95.
• On Friday, October 3rd, Endurance (Cayman) Ltd Svf sold 450,342 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.56, for a total transaction of $2,503,901.52.

Vir Biotechnology Stock Performance

Shares of VIR stock opened at $5.78 on Monday. Vir Biotechnology, Inc. has a 52-week low of $4.16 and a 52-week high of $14.45. The company has a 50-day simple moving average of $5.16 and a two-hundred day simple moving average of $5.27. The company has a market capitalization of $802.96 million, a price-to-earnings ratio of -1.45 and a beta of 1.27.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). Vir Biotechnology had a negative return on equity of 50.22% and a negative net margin of 2,895.94%.The firm had revenue of $1.21 million during the quarter, compared to the consensus estimate of $2.38 million. During the same period in the previous year, the company posted ($1.02) earnings per share. The company’s revenue for the quarter was down 60.5% on a year-over-year basis. On average, sell-side analysts forecast that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Analysts Set New Price Targets

VIR has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Tuesday, October 14th. Bank of America raised shares of Vir Biotechnology from a “neutral” rating to a “buy” rating and increased their target price for the company from $12.00 to $14.00 in a research report on Wednesday, August 27th. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Vir Biotechnology in a research report on Monday, September 15th. Raymond James Financial initiated coverage on shares of Vir Biotechnology in a research report on Friday, July 11th. They set an “outperform” rating for the company. Finally, Evercore ISI initiated coverage on shares of Vir Biotechnology in a research report on Wednesday, September 3rd. They set an “outperform” rating and a $12.00 target price for the company. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $17.30.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Raymond James Financial Inc. bought a new position in Vir Biotechnology in the 2nd quarter worth approximately $35,000. GAMMA Investing LLC boosted its holdings in Vir Biotechnology by 524.3% in the 1st quarter. GAMMA Investing LLC now owns 7,111 shares of the company’s stock worth $46,000 after buying an additional 5,972 shares during the period. Apollon Wealth Management LLC bought a new position in Vir Biotechnology in the 2nd quarter worth approximately $50,000. PNC Financial Services Group Inc. boosted its holdings in Vir Biotechnology by 26.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 10,459 shares of the company’s stock worth $68,000 after buying an additional 2,171 shares during the period. Finally, FORA Capital LLC bought a new position in Vir Biotechnology in the 1st quarter worth approximately $70,000. 65.32% of the stock is owned by institutional investors.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).